u/zeynep_mbeki

The thing that surprised me was how much of the discussion here is inference rather than measurement.

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

maintenance is a phase, not a finish line

This reframing is the most useful thing on the board for anyone approaching this phase.

Stretched from seven to ten days and then to twelve over about four months. Appetite told me where the limit was before the scale did.

seven days to ten to twelve is the sequence people here describe

Sent a vial to Medutest out of curiosity. Result was 97.5% against a claimed 97.0%, which is the first independent number I had seen for this compound anywhere.

I would not treat a two-kilo range as drift requiring action. That is ordinary weight variation.

Yes — the glucagon arm is what makes it a different proposition rather than a stronger version of the others.

triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part

Disagree with chasing the last stretch by going up. You are trading a real side-effect cost for a number you chose arbitrarily.

Chased the last three kilos with a dose increase and got a fortnight of nausea and no change in the number.

Correction: that trial measured regain after withdrawal, not failure of the drug during treatment. Very different claim.

Kept a log specifically because there is so little published. It is one person and it is not data.

the TRIUMPH programme is still running, so anything definitive is premature

Kept a log specifically because there is so little published. It is one person and it is not data.

Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.

maintenance is a phase, not a finish line

the escalation is where most of the reported trouble sits

Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

This. The phase 2 result was genuinely large and it was also 48 weeks in a few hundred people.

Two years at maintenance. The logistics are the only remaining work — ordering, storing, remembering.

Drifted up 2kg over a winter and panicked. It came back off without any change, which is apparently just what weight does.

The sulphur burps profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.

find the dose that holds, then stop optimising

None of this is a taper plan. What dose holds for you is a question for somebody with your history in front of them.

Kept a log specifically because there is so little published. It is one person and it is not data.

the glucagon component is why the metabolic story reads differently

That is a range, not a trend. Two weigh-ins 21 days apart cannot distinguish them.

Withdrawal studies in this class consistently show substantial regain after discontinuation. That is a pharmacological finding about a chronic condition, not a statement about anyone’s discipline.

Wrote down what maintenance would look like at about week 54, before I needed it. Having decided in advance made the transition boring.

This. The withdrawal data is not ambiguous and framing regain as a personal failure is both wrong and cruel.

Cosigning the escalation point. Almost every difficult report on this board is from somebody who went up quickly.

It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.

That reads like a taper schedule and this board cannot hand those out.

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

Wrote down what maintenance would look like at about week 44, before I needed it. Having decided in advance made the transition boring.

What do you think the glucagon component is adding, specifically?

Small fix — you have described interval stretching and called it a dose reduction. The exposure profiles differ.

Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.